Evidence map›Paper›PMID 36105695›Full record

ArticleJournal of hepatocellular carcinoma2022

Impaired Autophagy Response in Hepatocellular Carcinomas Enriches Glypican-3 in Exosomes, Not in the Microvesicles.

Ali Riza Koksal, Paul Thevenot, Yucel Aydin, Kelley Nunez, Tyler Sandow, Kyle Widmer, Leela Nayak, John Scott, Molly Delk, Martin W Moehlen and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of hepatocellular carcinoma, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Ali Riza KoksalDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA.
Paul ThevenotDepartment of Gastroenterology and Hepatology, Institute of Translational Research, Ochsner Health, New Orleans, LA, USA.
Yucel AydinDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA.
Kelley NunezDepartment of Gastroenterology and Hepatology, Institute of Translational Research, Ochsner Health, New Orleans, LA, USA.
Tyler SandowDepartment of Radiology, Multi-Organ Transplant Institute, Ochsner Health, New Orleans, LA, USA.
Kyle WidmerSoutheast Louisiana Veterans Health Care System, New Orleans, LA, USA.
Leela NayakSoutheast Louisiana Veterans Health Care System, New Orleans, LA, USA.
John ScottDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA.
Molly DelkDepartment of Gastroenterology and Hepatology, Tulane University Health Sciences Center, New Orleans, LA, USA.
Martin W MoehlenDepartment of Gastroenterology and Hepatology, Tulane University Health Sciences Center, New Orleans, LA, USA.
Ari J CohenDepartment of Gastroenterology and Hepatology, Institute of Translational Research, Ochsner Health, New Orleans, LA, USA.
Srikanta DashDepartment of Pathology and Laboratory Medicine, Tulane University Health Sciences Center, New Orleans, LA, USA.
Tulane University · USOchsner Health System · USSoutheast Louisiana Veterans Health Care System · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
BLRD VA I01 BX004516NIGMS NIH HHS U54 GM104940
6 · The paper itself

Abstract

Background and Aim: HCC development in liver cirrhosis is associated with impaired autophagy leading to increased production of extracellular vesicles (EVs) including exosomes and microvesicles. The goal of the study is to determine which of these particles is primarily involved in releasing of HCC-specific biomarker glypican-3 (GPC3) when autophagy is impaired. Methods: Streptavidin-coated magnetic beads were coupled with either biotinylated CD63 or Annexin A1 antibodies. Coupled beads were incubated with EVs isolated from either HCC culture or serum. EVs captured by immuno-magnetic beads were then stained with FITC or PE fluorescent-conjugated antibodies targeting exosomes (CD81), and microvesicles (ARF6). The percentage of GPC3 enrichment in the microvesicles and exosomes was quantified by flow cytometry. The impact of autophagy modulation on GPC3 enrichment in exosomes and microvesicles was assessed by treating cells with Torin 1 and Bafilomycin A1. For clinical validation, GPC3 content was quantified in microvesicles, and exosomes were isolated from the serum of patients with a recent HCC diagnosis. Results: The immune-magnetic bead assay distinguishes membrane-derived microvesicles from endosome-derived exosomes. The GPC3 expression was only seen in the CD63 beads group but not in the Annexin A1 beads group, confirming that in HCC, GPC3 is preferentially released through exosomes. Furthermore, we found that autophagy induction by Torin1 decreased GPC3-positive exosome secretion and decreased microvesicle release. Conversely, autophagy inhibition by Bafilomycin A1 increased the secretion of GPC3-positive exosomes. Serum analysis showed CD81+ve EVs were detected in exosomes and ARF6+ve vesicles were detected in microvesicles, suggesting that immunoaffinity assay is specific. The exosomal GPC3 enrichment was confirmed in isolated EVs from the serum of patients with HCC. The frequency of GPC3-positive exosomes was higher in patients with HCC (12.4%) compared to exosomes isolated from non-cirrhotic and healthy controls (3.7% and 1.3% respectively, p<0.001). Conclusion: Our results show that GPC3 is enriched in the endolysosomal compartment and released in exosome fractions when autophagy is impaired.

Indexed as

biomarkerexosomeglypican 3hepatocellular carcinomamagnetic beads

Identifiers

PMID36105695
PMCPMC9464631
OpenAlexW4295034915

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.